Inari Medical
General Information | |
Business: |
We are a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Our initial product offering consists of two minimally-invasive, novel catheter-based mechanical thrombectomy devices. We purpose-built our products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE – deep vein thrombosis and pulmonary embolism. Our ClotTriever product is FDA-cleared for the removal of clot from peripheral blood vessels and is used to treat patients suffering from deep vein thrombosis, or DVT. Our FlowTriever product is the first thrombectomy system FDA-cleared for the treatment of pulmonary embolism, or PE. |
Industry: | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Employees: | 240 |
Founded: | 2011 |
Contact Information | |
Address | 9 Parker, Suite 100, Irvine, CA 92618, US |
Phone Number | (877) 923-4747 |
Web Address | http://www.inarimedical.com |
View Prospectus: | Inari Medical |
Financial Information | |
Market Cap | $806.4mil |
Revenues | $71.1 mil (last 12 months) |
Net Income | $3.9 mil (last 12 months) |
IPO Profile | |
Symbol | NARI |
Exchange | NASDAQ |
Shares (millions): | 8.2 |
Price range | $19.00 - $19.00 |
Est. $ Volume | $155.8 mil |
Manager / Joint Managers | BofA Securities/Morgan Stanley |
CO-Managers | Canaccord Genuity/ Wells Fargo Securities |
Expected To Trade: | 5/22/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |